BTOG 2022 | Treating mesothelioma with checkpoint inhibitors

Paul Baas, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, describes the role of immune checkpoint inhibitors in treating mesothelioma. Current chemotherapy regimens are inadequate and provide limited efficacy, especially in non-epithelioid mesothelioma. Recent research has suggested that ipilimumab and nivolumab have demonstrated superior efficacy compared to standard chemotherapy in patients with mesothelioma. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.